Company Profile
Synaptogenix Stock Price, News & Catalysts
- Ticker:
- SNPX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
24.55 USD (+1.20%)
Close
Last updated: April 20, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for SNPX.
Company overview
Business overview
Synaptogenix is a biotechnology company focused on neurodegenerative disease and synaptic biology. Its story centers on trying to translate brain-health science into therapies for difficult neurologic conditions.
Geographic Base and Sector Classification
Synaptogenix is headquartered in the United States and listed on NASDAQ. It sits in small-cap neuroscience biotechnology.
Business Model Characteristics
The company depends on clinical and translational progress, capital efficiency, and the ability to maintain a focused neurologic thesis. Investors usually watch early data and strategic direction.
Position Within the Biotechnology Landscape
Synaptogenix occupies a small neuroscience niche within biotech. It remains catalyst-sensitive because the company still needs to prove its platform in a difficult disease area.
Future catalysts
- Synaptogenix is a legacy / closeout story now, with catalysts limited to any strategic update. The market is not treating it like an active growth story.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Synaptogenix (SNPX)?
Synaptogenix (SNPX) most recently closed at 24.55 USD, a +1.20% move versus the previous session.
What does Synaptogenix do?
Synaptogenix is a biotechnology company focused on neurodegenerative disease and synaptic biology. Its story centers on trying to translate brain-health science into therapies for difficult neurologic conditions.
On which exchange is SNPX stock listed?
Synaptogenix (SNPX) is associated with NASDAQ, United States, Biopharma.
What is Synaptogenix?
Synaptogenix is a legacy / closeout story now, with catalysts limited to any strategic update.
Which conditions is Synaptogenix targeting with Synaptogenix?
Synaptogenix is a legacy / closeout story now, with catalysts limited to any strategic update.
How does Synaptogenix describe recent progress with Synaptogenix?
Synaptogenix is a legacy / closeout story now, with catalysts limited to any strategic update.
What future catalysts are investors watching for Synaptogenix?
Synaptogenix is a legacy / closeout story now, with catalysts limited to any strategic update. The market is not treating it like an active growth story.